Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Syringe exchange clinics offer new hope for opioid addiction treatment

NCT ID NCT03150173

Disease control Sponsor: Montefiore Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether giving buprenorphine treatment directly at syringe exchange programs helps people with opioid addiction more than sending them to a community health center. About 100 syringe exchange participants in New York City took part. The goal was to see if starting treatment on-site leads to more people staying on their medication and reducing HIV risk behaviors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

97 people

The number who actually took part.

Started

Jan 2019

Finished

Mar 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. age ≥ 18 years 2. opioid use disorder 3. interest in buprenorphine treatment 4. motivation for opioid use disorder treatment 5. willingness to accept community health center referral 6. syringe exchange participant Exclusion Criteria: 1. receiving opioid agonist treatment in the past 30 days (confirmed by New York Prescription Drug Monitoring Program); 2. inability to provide informed consent 3. unstable mental illness (e.g., suicidality, psychosis, etc.) 4. severe alcohol use disorder or benzodiazepine use disorder by the Diagnostic and Statistical Manual of Mental disorders, Fifth Edition (DSM-5) criteria 5. hypersensitivity to buprenorphine or naloxone. 6. pregnancy (confirmed via urine testing)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Opiate addiction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Opiate addiction

Contacts and locations

Locations

  • BOOM!Health Harm Reduction Center

    The Bronx, New York, 10451, United States

  • New York Harm Reduction Educators

    New York, New York, 10035, United States

  • Washington Heights CORNER Project

    New York, New York, 10033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.